151 related articles for article (PubMed ID: 31006307)
1. Disposition of asciminib, a potent BCR-ABL1 tyrosine kinase inhibitor, in healthy male subjects.
Tran P; Hanna I; Eggimann FK; Schoepfer J; Ray T; Zhu B; Wang L; Priess P; Tian X; Hourcade-Potelleret F; Einolf HJ
Xenobiotica; 2020 Feb; 50(2):150-169. PubMed ID: 31006307
[TBL] [Abstract][Full Text] [Related]
2. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.
Manley PW; Barys L; Cowan-Jacob SW
Leuk Res; 2020 Nov; 98():106458. PubMed ID: 33096322
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.
Schoepfer J; Jahnke W; Berellini G; Buonamici S; Cotesta S; Cowan-Jacob SW; Dodd S; Drueckes P; Fabbro D; Gabriel T; Groell JM; Grotzfeld RM; Hassan AQ; Henry C; Iyer V; Jones D; Lombardo F; Loo A; Manley PW; Pellé X; Rummel G; Salem B; Warmuth M; Wylie AA; Zoller T; Marzinzik AL; Furet P
J Med Chem; 2018 Sep; 61(18):8120-8135. PubMed ID: 30137981
[TBL] [Abstract][Full Text] [Related]
4. Development of asciminib, a novel allosteric inhibitor of BCR-ABL1.
Réa D; Hughes TP
Crit Rev Oncol Hematol; 2022 Mar; 171():103580. PubMed ID: 35021069
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases.
Li YF; Combes FP; Hoch M; Lorenzo S; Sy SKB; Ho YY
Clin Pharmacokinet; 2022 Oct; 61(10):1393-1403. PubMed ID: 35764773
[TBL] [Abstract][Full Text] [Related]
6. High Efficacy and Safety of Asciminib in a Chronic Myeloid Leukemia Patient with Chronic Kidney Disease Following Renal Transplantation.
Uchida Y; Koyama D; Manabe K; Suzuki K; Asano N; Endo M; Fukatsu M; Sano T; Hayashi K; Takano M; Takahashi H; Kimura S; Ikezoe T
Intern Med; 2024 Mar; 63(5):717-720. PubMed ID: 37407456
[TBL] [Abstract][Full Text] [Related]
7. Allosteric enhancement of the BCR-Abl1 kinase inhibition activity of nilotinib by cobinding of asciminib.
Oruganti B; Lindahl E; Yang J; Amiri W; Rahimullah R; Friedman R
J Biol Chem; 2022 Aug; 298(8):102238. PubMed ID: 35809644
[TBL] [Abstract][Full Text] [Related]
8. A kinase inhibitor which specifically targets the ABL myristate pocket (STAMP), but unlike asciminib crosses the blood-brain barrier.
Manley PW; Huth F; Moussaoui S; Schoepfer J
Bioorg Med Chem Lett; 2022 Mar; 59():128577. PubMed ID: 35065232
[TBL] [Abstract][Full Text] [Related]
9. Asciminib: First Approval.
Deeks ED
Drugs; 2022 Feb; 82(2):219-226. PubMed ID: 35041175
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic drug interactions of asciminib with the sensitive cytochrome P450 probe substrates midazolam, warfarin, and repaglinide in healthy participants.
Hoch M; Sengupta T; Hourcade-Potelleret F
Clin Transl Sci; 2022 Jun; 15(6):1406-1416. PubMed ID: 35293131
[TBL] [Abstract][Full Text] [Related]
11. Molecular dynamics investigation on the Asciminib resistance mechanism of I502L and V468F mutations in BCR-ABL.
Zhan JY; Ma J; Zheng QC
J Mol Graph Model; 2019 Jun; 89():242-249. PubMed ID: 30927708
[TBL] [Abstract][Full Text] [Related]
12. An evaluation of asciminib for patients with chronic myeloid leukemia previously treated with ≥2 tyrosine kinase inhibitors.
García-Gutiérrez V; Hernandez-Boluda JC
Expert Rev Hematol; 2022 Jun; 15(6):477-484. PubMed ID: 35583386
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of Asciminib in Individuals With Hepatic or Renal Impairment.
Hoch M; Sato M; Zack J; Quinlan M; Sengupta T; Allepuz A; Aimone P; Hourcade-Potelleret F
J Clin Pharmacol; 2021 Nov; 61(11):1454-1465. PubMed ID: 34115385
[TBL] [Abstract][Full Text] [Related]
14. Absorption, metabolism, and excretion of [
Ye YE; Woodward CN; Narasimhan NI
Cancer Chemother Pharmacol; 2017 Mar; 79(3):507-518. PubMed ID: 28184964
[TBL] [Abstract][Full Text] [Related]
15. Asciminib and ponatinib combination in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Zerbit J; Tamburini J; Goldwirt L; Decroocq J; Cayuela JM; Chapuis N; Contejean A; Batista R; Bouscary D; Willems L
Leuk Lymphoma; 2021 Dec; 62(14):3558-3560. PubMed ID: 34405773
[No Abstract] [Full Text] [Related]
16. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
[TBL] [Abstract][Full Text] [Related]
17. In vitro evidence of synergistic efficacy with asciminib combined with reduced dose of ATP-binding pocket tyrosine kinase inhibitors according to the ABL1 kinase domain mutation profile.
Han HJ; Kim JJ; Pyne D; Travas A; Ambalavanan A; Kimura S; Deininger MW; Kim JW; Kim DDH
Leukemia; 2024 Feb; 38(2):412-415. PubMed ID: 38155246
[No Abstract] [Full Text] [Related]
18. Pharmacokinetics of Asciminib When Taken With Imatinib or With Food.
Hoch M; Zack J; Quinlan M; Huth F; Forte S; Dodd S; Aimone P; Hourcade-Potelleret F
Clin Pharmacol Drug Dev; 2022 Feb; 11(2):207-219. PubMed ID: 34609077
[TBL] [Abstract][Full Text] [Related]
19. Initial results with asciminib in CML.
Romero D
Nat Rev Clin Oncol; 2020 Mar; 17(3):135. PubMed ID: 31900441
[No Abstract] [Full Text] [Related]
20. Pharmacokinetics of asciminib in the presence of CYP3A or P-gp inhibitors, CYP3A inducers, and acid-reducing agents.
Hoch M; Huth F; Sato M; Sengupta T; Quinlan M; Dodd S; Kapoor S; Hourcade-Potelleret F
Clin Transl Sci; 2022 Jul; 15(7):1698-1712. PubMed ID: 35616006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]